Christina Lindahl

High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk

Wim A. van der Steeg, Ingar Holme, S. Matthijs Boekholdt et al. · Journal of the American College of Cardiology · 2008 · 378 citations

Life Sciences, Biochemistry, Lipid Biochemistry +16

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

Ingar Holme, Rana Fayyad, Sonal Bhatia et al. · The American Journal of Cardiology · 2009 · 153 citations

Medicine, Cardiology, Pharmacology +15

Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy

Matti J. Tikkanen, Michael Szarek, Rana Fayyad et al. · Journal of the American College of Cardiology · 2009 · 65 citations

Medicine, Cardiology, Internal Medicine +13

Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)

Matti J. Tikkanen, Ingar Holme, Nilo B. Cater et al. · The American Journal of Cardiology · 2009 · 56 citations

Medicine, Cardiology, Pharmacotherapy +15

Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study

Terje R. Pedersen, John J.P. Kastelein, Anders Olsson et al. · The American Journal of Cardiology · 2004 · 54 citations

Pharmacy, Pharmacology, Lipid Biochemistry +10